[Evaluation of pharmaceutical intervention to patients in the community through telepharmacy]. [PDF]
Farm ComunitariosDelgado-Pérez GM +4 more
europepmc +1 more source
Miltefosine implementation for treatment of cutaneous leishmaniasis: access indicators in the state of Minas Gerais, 2021-2024. [PDF]
Epidemiol Serv SaudeSilva SN, Saliba MF, Ribeiro LR, Cota G.
europepmc +1 more source
[Drug shortages in Family Medicine practice]. [PDF]
Aten PrimariaEsteban-Jiménez Ó +1 more
europepmc +1 more source
Care and primary health care access indicators among Brazilian adults with diabetes mellitus, National Health Survey 2019. [PDF]
Rev Bras EpidemiolTonaco LAB +4 more
europepmc +1 more source
[Pharmaceutical services in expanded access, compassionate use, and post-trial access: the perspective of clinical researchers]. [PDF]
Cad Saude PublicaSilva MBFCD, Silva CFD, Silva MJSD.
europepmc +1 more source
Drugs incorporated into the Brazilian Unified Health System: document analysis of methodological decisions in budget impact analyses between 2012 and 2024. [PDF]
Epidemiol Serv SaudeCurado DDSP, Silva END.
europepmc +1 more source
Medicamentos, cantidad y calidad [PDF]
Anales del Sistema Sanitario de Navarra, 2009 openaire +4 more sources
Beta-blockers for Hypertension: To Be or Not to Be a First-line Drug? [PDF]
Arq Bras CardiolBarreto-Filho JAS +3 more
europepmc +1 more source
Eosinofilia secundaria a medicamentos
Se considera eosinofilia cuando el número total de eosinófilos circulantes en sangre periférica es significativamente superior al presente en la población general. Estos valores pueden variar según distintos autores, pero en su mayoría coinciden en considerar eosinofilia como igual o mayor a 450/μL.
Leal, Ángel +2 more
openaire +1 more source